JP Morgan Upgrades Immunogen to Overweight, Raises Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Daniel Wolle has upgraded Immunogen (NASDAQ:IMGN) from Neutral to Overweight and raised the price target from $9 to $22.
September 13, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunogen's stock has been upgraded by JP Morgan from Neutral to Overweight, with a price target increase from $9 to $22.
The upgrade from JP Morgan is a positive signal for Immunogen. The significant increase in the price target suggests that the analyst sees substantial upside potential in the stock. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100